Table 1.
Clinical profile of the sample and their bioelectrical impedance analysis (BIA) measurements.
| Characteristics | Patients (n = 17) | Controls (n = 17) | Statistical Tests, p Value | Holm’s-Adjusted Alpha Levels | Rank | Outcome of Holm’s Adjusted Alpha Levels |
|---|---|---|---|---|---|---|
| (25th–75th Percentiles) | (25th–75th Percentiles) | |||||
| Age (years) | 27 (22–29) | 26 (22–28) | M-W U test = 134, p = 0.73 | 0.199 | 12 | Non-significant |
| Clinical and Biochemical Hyperandrogenism | 15 (88.23%) | - | - | |||
| Polycystic ovaries on Ultrasound | 12 (70.58%) | - | - | |||
| Menstrual Problems | 14 (82.35%) | - | - | |||
| Metformin + OCPs | 17 (100%) | - | - | |||
| BMI | 22 (19.7–24.5) | 22 (20.43–24.51) | M–W U test = 136, p = 0.76 | 0.199 | 13 | Non-significant |
| TBW (L) | 27.8 (27.3–29.3) | 31.2(28.2–34.9) | M–W U test = 80.5, p = 0.026 | 0.110 | 4 | Significant |
| ECW (%TBW) | 47 (46–49) | 42.5 (40.16–43.22) | M–W U test = 10, p < 0.001 | 0.082 | 1 | Significant |
| ICW (%TBW) | 53 (51–54) | 57.5 (56.78–59.84) | M–W U test = 10, p < 0.001 | 0.082 | 1 | Significant |
| ICW (L) | 14.9 (13.9–15.8) | 18 (15.8–21.1) | M–W U test = 57, p = 0.0025 | 0.099 | 3 | Significant |
| FFM (Kg) | 44.5 (43.1–46.8) | 47.3 (44.3–52.6) | M–W U test = 87, p = 0.05 | 0.165 | 8 | Significant |
| FM (%Weight) | 27 (19–31) | 26.27 (21.83–27.47) | M–W U test = 133, p = 0.69 | 0.199 | 9 | Non-significant |
| FM (Kg) | 13 (9.7–20.9) | 17.9 (12.5–19.2) | M–W U test = 133, p = 0.70 | 0.199 | 10 | Non-significant |
| Phase Angle (degrees °) | 3.4 (2.6–4.2) | 6.9 (5.8–8.4) | M–W U test = 24, p < 0.001 | 0.082 | 1 | Significant |
| TBPro (Kg) | 7.51 (7.05–7.95) | 8.991 (7.94–10.47) | M–W U test = 59, p = 0.003 | 0.124 | 5 | Significant |
| TBPro (%FFM) | 16.67 (16.4–17.47) | 18.692 (17.8–19.91) | M–W U test = 19, p < 0.001 | 0.082 | 1 | Significant |
| Gly (Kg) | 0.331 (0.31–0.35) | 0.4 (0.35–0.46) | M–W U test = 60, p = 0.004 | 0.142 | 6 | Significant |
| Gly (%FFM) | 0.73 (0.72–0.77) | 0.82 (0.78–0.88) | M–W U test = 20, p < 0.001 | 0.082 | 1 | Significant |
| Bm (Kg) | 1.64 (1.61–1.74) | 1.91 (1.69–2.09) | M–W U test = 78, p = 0.021 | 0.090 | 2 | Significant |
| Skeletal Muscles (Kg) | 13.9 (12.9–14.8) | 17.04 (14.79–20.2) | M–W U test = 60, p = 0.004 | 0.142 | 6 | Significant |
| Skeletal Muscles (%FFM) | 31.1 (29.3–32.4) | 35.37 (33.16–38.4) | M–W U test = 28, p < 0.001 | 0.082 | 1 | Significant |
| Bones (Kg) | 3 (3–3.2) | 3.53 (3.13–3.88) | M–W U test = 74, p = 0.014 | 0.165 | 7 | Significant |
| ALST (Kg) | 12 (11.1–12.7) | 14.74 (12.72–17.44) | M–W U test = 58, p = 0.003 | 0.110 | 5 | Significant |
| ALST (%FFM) | 26.8 (25.1–28.1) | 30.64 (28.52–33.16) | M–W U test = 27, p < 0.001 | 0.082 | 1 | Significant |
| AAT (cm2) | 191.2 (135.6–324.5) | 273.88 (182.82–295.8) | M–W U test = 134, p = 0.71 | 0.199 | 11 | Non-significant |
| AT (Kg) | 16.3 (12.1–26.1) | 22.38 (15.63–24) | M–W U test = 133, p = 0.70 | 0.199 | 10 | Non-significant |
| AT (%Weight) | 33.2 (23.9–39) | 32.84 (27.29–34.34) | M–W U test = 134, p = 0.71 | 0.199 | 11 | Non-significant |
| Sarcopenia | 13/17 (76.47%) | 1/17 (5.88%) | x2 = 3414.167, df = 33, p < 0.001, RR = 4.643, 95% CI: 1.985–6.526 | Significant | ||
Abbreviations: M–W U test = Mann–Whitney U test, x2 = Chi-squared test, p = p-value, = Median value, OCP = Oral contraceptive pill, BMI = Body mass index, TBW (%Weight) = Total body water (as percent of weight), ECW = Extracellular water, ICW = Intracellular water, FFM = Fat free mass, FM = Fat mass, TBPro = Total body protein, Gly = Glycogen, Bm = Bone minerals, ALST = Appendicular lean soft tissue, AAT = Abdominal adipose tissue, AT = Adipose tissue.